Alzheimer’s Association Facts and Figures. 2024. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf.

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3. https://doi.org/10.1126/science.8346443.

Article  CAS  PubMed  Google Scholar 

Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400. https://doi.org/10.1146/annurev.med.47.1.387.

Article  CAS  PubMed  Google Scholar 

Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38:1–17. https://doi.org/10.1159/000334607.

Article  PubMed  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. https://doi.org/10.1056/NEJMoa2212948.

Article  PubMed  Google Scholar 

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367–85. https://doi.org/10.1016/j.jalz.2011.05.2351.

Article  PubMed  Google Scholar 

Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414–24. https://doi.org/10.1093/brain/awad188.

Article  PubMed  PubMed Central  Google Scholar 

Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of amyloid- related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211–20. https://doi.org/10.14283/jpad.2022.21.

Article  CAS  PubMed  Google Scholar 

Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm. 2004;1:24. https://doi.org/10.1186/1742-2094-1-24.

Article  CAS  Google Scholar 

Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathways. Nat Rev Neurol. 2020;16:30–42. https://doi.org/10.1038/s41582-019-0281-2.

Article  CAS  PubMed  Google Scholar 

Rannikmäe K, Kalaria RN, Greenberg SM, Chui HC, Schmitt FA, Samarasekera N, et al. APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85:300–5. https://doi.org/10.1136/jnnp-2013-306485.

Article  PubMed  Google Scholar 

Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 2022;79:228–43. https://doi.org/10.1001/jamaneurol.2021.5216.

Article  PubMed  Google Scholar 

Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti- amyloid antibodies for the treatment of dementia due to Alzheimer’s disease. Front Neurol. 2022;13: 862369. https://doi.org/10.3389/fneur.2022.862369.

Article  PubMed  PubMed Central  Google Scholar 

Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95. https://doi.org/10.1186/s13195-020-00663-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021;22(12):6355. https://doi.org/10.3390/ijms22126355.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tolar M, Hey JA, Power A, Abushakra S. The single toxin origin of Alzheimer’s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024;25(5):2727. https://doi.org/10.3390/ijms25052727.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, et al. Elucidating the abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer’s disease: integrating molecular analytical Methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31(6):495–509. https://doi.org/10.1007/s40263-017-0434-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnalek M, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018;32(9):849–61. https://doi.org/10.1007/s40263-018-0554-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang C, Savinov SN, Fejzo J, Eyles SJ, Chen J. Modulation of amyloid-beta42 conformation by small molecules through nonspecific binding. J Chem Theory Comput. 2019;15(10):5169–74. https://doi.org/10.1021/acs.jctc.9b00599.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57(3):315–33. https://doi.org/10.1007/s40262-017-0608-3.

Article  CAS  PubMed  Google Scholar 

Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, et al. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the “APOE4 gene-dose effect.” J Prev Alz Dis. 2016;3(4):219–28. https://doi.org/10.14283/jpad.2016.115.

Article  CAS  Google Scholar 

Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, et al. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potential. J Prev Alzeimers Dis. 2017;4(3):149–56. https://doi.org/10.14283/jpad.2017.26.

Article  CAS  Google Scholar 

Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid peptide. J Neurosci. 2012;32:15181–92. https://doi.org/10.1523/JNEUROSCI.1542-12.2012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1–12. https://doi.org/10.1016/j.neurobiolaging.2012.04.017.

Article  CAS  PubMed  Google Scholar 

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1939–49. https://doi.org/10.1001/jama.2015.4669.

Article  PubMed  PubMed Central  Google Scholar 

Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaque-Alcazar L, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer’s disease. Nat Med. 2024;30(5):1284–91. https://doi.org/10.1038/s41591-024-02931-w.

Article  CAS  PubMed  Google Scholar 

Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.

Article  Google Scholar 

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of